While Brivaracetam is being evaluated as an adjunctive therapy in patients diagnosed with Epilepsy and partial onset seizures, animal models have piqued the curiosity of R&D experts as to Brivaracetam being a potential treatment for Alzheimer’s patients. As a unique product with a high-affinity synaptic vesicle protein 2A ligand, Brivaracetam is currently marketed by UCB,[…]
Can Brivaracetam Reverse Memory Impairment in Alzheimer’s Patients?
Anticonvulsant, Drug Research & Development API Tags: AlzheimersepilepsyEUJanssen Pharmaceuticals Jul 30, 2015
Early EU Approval for Ibrutinib
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, EU Approved 2014, FDA Priority Status Tags: CLLEUIbrutinib Oct 21, 2014
The early EU approval for Ibrutinib was granted by the European Commission (EC), for Ibrutinib to be sold in the 28 European Union (EU) member states. Ibrutinib is a first-in-class, oral, once-daily, non-chemotherapy treatment option, and will be used to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).[…]
Regorafenib Proves to Show Additional Benefits
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2020 Tags: EUregorafenib Apr 28, 2014
Regorafenib is a formidable treatment for colon cancer, and in late 2013 it has received another new approval for GIST in Japan and Europe. Known as the trade name Stivarga, Regorafenib was approved in both Japan and Europe for the treatment of gastrointestinal stromal tumors. The FDA approved Regorafenib two years ago and added the[…]
EU Approves Cabozantinib for Metastatic Medullary Thyroid Carcinoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, EU Approved 2014 Tags: EGFREU Apr 17, 2014
The end of March 2014 brought exciting news from the EU with the announcement of their approval of Cabozantinib for unresectable medullary thyroid carcinoma. Known as the brand name Cometriq and marketed by Exelixis, Cabozantinib works by inhibiting the activity of MET, RET and VEGFR tyrosine kinases. Cases of medullary thyroid carcinoma are virulent and[…]
EU Approves Albiglutide for Type 2 Diabetes
Anti-Diabetic, FDA Approved 2014 Tags: EUGlaxoSmithKline Apr 07, 2014
On March 27, 2014, the EU announced their approval of Albiglutide for patients diagnosed with Type 2 Diabetes. This approval was expected by GlaxoSmithKline, as Albiglutide, known as their brand name drug Eperzan, received a positive opinion from the EU at the commencement of 2014. The unique ability of Albiglutide to act as an effectual[…]
Propranolol Hydrochloride U.S. & E.U. Approved to Treat Infantile Hemangioma
Anti-Migraine, Drug Research & Development API, EU Approved 2014, FDA Approved 2014 Tags: EU Mar 28, 2014
UPDATE: On May 6, 2014, Propranolol was approved by the European Commission for treatment of infantile hemangioma. Infantile hemangioma, or an overgrowth of blood vessels on or under the skin of infants is a benign vascular condition. As a common non-life threatening tumor of the skin, infantile hemangioma occur during the first four weeks of[…]
EU Approves Dimethyl Fumarate for First Line MS Treatment
Drug Research & Development API, EU Approved 2014, Immunosuppressant Tags: EURRMS Feb 17, 2014
Dimethyl Fumarate was approved by the EU at the beginning of February 2014 as a first line treatment for multiple sclerosis. Known as the brand name TECFIDERA, which is marketed by Biogen Inc., this efficacious and novel treatment is specified for patients with the most common form of multiple sclerosis, relapsing-remitting multiple sclerosis, or RRMS.[…]
EU Offers Positive Opinion for Type 2 Diabetes Drug Albiglutide
Anti-Diabetic, Drug Research & Development API Tags: EUtype 2 Diabetes Feb 14, 2014
The EU has offered a positive opinion to GlaxoSmithKline for their type 2 diabetes drug Albiglutide, known as the brand name Eperzan. The unique once weekly dosage of this GLP-1 receptor agonist is only one of the reasons for a hopeful EU approval in the near future. Albiglutide is intended as a monotherapy for patients[…]
Regorafenib Tablet Gains EU Approval for Colorectal Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, EU Approved 2013 Tags: EGFREUregorafenib Sep 03, 2013
The Regorafenib tablet gains EU approval for the treatment of metastasized colorectal cancer (mCRC) in adults, whose disease has progressed even after treatment with standard drugs. Regorafenib was previously approved by the FDA in late May 2012 to treat patients with metastatic colorectal cancer. That initial approval of Regorafenib for unresectable colon cancer was based on the[…]
Rilpivirine Proves to be a Worthy HIV Opponent
Anti-Retroviral / Anti-HIV, Antiviral, FDA Approved 2011 Tags: EUHIV infectionvitamin D Nov 28, 2012
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor {NTRI} known as the brand name Edurant. Rilpivirine is used to treat HIV-1 infection, and it is often dispensed alongside other antiretroviral agents. As a 25 milligram tablet designed to be taken once daily with food, rilpivirine is effective at decreasing the amount of HIV infection in the[…]
- 1
- 2
